Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Services
Return to: PBR Home | Contract Research & Services | Contract Services

Contract Services

Ligand Pharmaceuticals licensing deals with Seelos Therapeutics for four programs Ligand Pharmaceuticals has licensed rights to four programs to Seelos Therapeutics a newly formed biopharmaceutical firm focused on central nervous system (CNS), respiratory and other disorders.
Contract Research & Services > Contract Services > News
Midatech Pharma US partners with R-Pharm US to co-promote Zuplenz and Oravig Midatech Pharma US has finalized a co-promotion agreement with R-Pharm US providing additional reach and frequency for the promotion of Zuplenz and Oravig to oncology accounts across the US.
Contract Research & Services > Contract Services > News Dr. Reddy’s expands collaboration with Amgen in India Dr. Reddy’s Laboratories has expanded its strategic collaboration with Amgen to market and distribute three of Amgen’s medicines in India in the therapy areas of oncology and osteoporosis.
Contract Research & Services > Contract Services > News
See more Contract Services news

Latest Contract Services News and Insight

View all Contract Services news or find news targeted to your interests
Alliance Pharma secures rights to pregnancy nausea drug in key EU countries
Alliance Pharma has signed a further licensing and distribution agreement with Duchesnay of Canada for Diclectin, a proven product to treat nausea and vomiting of pregnancy.
Contract Research & Services > Contract Services > News
MacroGenics regains global rights to DART molecule for autoimmune disorders
MacroGenics and Takeda Pharmaceutical Company announced the conclusion of their license and option agreement for MGD010.
Contract Research & Services > Contract Services > News
Redx signs deal with Quay Pharma to manufacture clinical trial supplies for Porcupine inhibitor
Redx Pharma has entered into an agreement with Quay Pharma to manufacture the clinical trial supplies for Redx’s Porcupine inhibitor (RXC004), which has the potential to tackle hard-to-treat cancers, such as pancreatic, triple negative breast and head and neck cancers.
Contract Research & Services > Contract Services > News
Aeterna Zentaris announces two new licensing deals for Zoptrex
Ergomed announced that its co-development partner, Aeterna Zentarisc has signed two further licensing deals for Zoptrex.
Contract Research & Services > Contract Services > News
TaiGen out-licenses Taigexyn to Productos Cientificos for Latin American market
TaiGen Biotechnology Company has signed an exclusive licensing agreement with Mexican pharmaceutical firm Productos Científicos (PC) to develop and commercialize Taigexyn (nemonoxacin) in Latin America.
Contract Research & Services > Contract Services > News
Celsion, Zhejiang Hisun sign deal to develop GEN-1 immuno-oncology therapy
Celsion has signed a long-term Technology Transfer, Manufacturing and Commercial Supply Agreement with Zhejiang Hisun Pharmaceutical to pursue an expanded partnership for the technology transfer relating to the clinical and commercial manufacture and supply of GEN-1, Celsion's gene mediated, IL-12 immunotherapy, for the greater China territory, with the option to expand into other countries in the rest of the world after all necessary regulatory approvals are in effect.
Contract Research & Services > Contract Services > News
Juno Therapeutics forms multiple myeloma partnership with MSK and Eureka Therapeutics
Juno Therapeutics has entered into an exclusive license agreement with Memorial Sloan Kettering Cancer Center (MSK) and Eureka Therapeutics for a novel, fully-human binding domain targeting B-cell maturation antigen (BCMA), along with binding domains against two additional undisclosed multiple myeloma targets to be used for the potential development and commercialization of chimeric antigen receptor (CAR) cell therapies for patients with multiple myeloma.
Contract Research & Services > Contract Services > News
Amgen secures rights to Advaxis’ cancer immunotherapy treatment
By PBR Staff Writer
Amgen has acquired global rights to a preclinical cancer immunotherapy treatment developed by Advaxis.
Contract Research & Services > Contract Services > News
Merck to offer Provantage end-to-end development and manufacturing services to Y-mAbs
Merck will provide its Provantage End-to-End development and manufacturing services to Y-mAbs Therapeutics in support of Y-mAbs' monoclonal antibody in late stage clinical development.
Contract Research & Services > Contract Services > News
View all Contract Services news or find news targeted to your interests